Savara Inc
SVRA
Company Profile
Business description
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Contact
1717 Langhorne Newtown Road
Suite 300
LanghornePA19047
USAT: +1 512 614-1848
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
59
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,579.90 | 50.10 | 0.59% |
| CAC 40 | 7,903.13 | 49.66 | 0.63% |
| DAX 40 | 23,866.72 | 171.13 | 0.72% |
| Dow JONES (US) | 42,322.75 | 271.69 | 0.65% |
| FTSE 100 | 8,688.31 | 54.56 | 0.63% |
| HKSE | 23,345.05 | 108.11 | -0.46% |
| NASDAQ | 19,112.32 | 34.49 | -0.18% |
| Nikkei 225 | 37,753.72 | 1.79 | -0.00% |
| NZX 50 Index | 12,786.79 | 94.03 | -0.73% |
| S&P 500 | 5,916.93 | 24.35 | 0.41% |
| S&P/ASX 200 | 8,343.70 | 46.20 | 0.56% |
| SSE Composite Index | 3,367.46 | 13.36 | -0.40% |